NCT05089916 2026-01-14
ROSE
AIO-Studien-gGmbH
Phase 2 Active not recruiting
Clinical Trials
7 trialsNCT05773092 2025-09-03
A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC
National Cancer Centre, Singapore
Phase 2 Active not recruiting
NCT06362980 2024-07-10
EGFR
National Cancer Center, China
Phase 1 Recruiting
NCT03810066 2024-05-09
Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS)
University Hospital, Essen
Phase 2 Completed
NCT04811001 2023-02-21
CAPLAND
Fondazione Ricerca Traslazionale
Phase 2 Unknown
NCT03394118 2021-04-27
TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid Biopsy
Asan Medical Center
Phase 2 Completed
NCT04575415 2020-10-20
BELLA
Guangdong Association of Clinical Trials
Unknown